Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on March 28, 2011. The filing discloses the execution of a new employment agreement with the company's Chief Financial Officer, Gerald Kochanski, effective April 1, 2011.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation terms.
- Base Salary: Increased to $200,192 annually (a 3% increase).
- Performance Bonus: Eligible for up to 20% of base salary based on personal and corporate targets.
- Relocation Allowance: Up to $10,000 for future relocation costs.
- Contract Term: Three years, ending March 31, 2014.
Material Changes Versus Prior Period
The new agreement replaces the prior contract which expired on March 31, 2011. Material changes include:
- Salary Adjustment: A 3% increase in base annual salary.
- Termination Provisions: New acceleration of unvested stock options if employment is terminated without "cause." Specifically, options that would have vested within the shorter of six months or the remainder of the term will immediately vest.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance or outlook. Key contractual terms and risks include:
- Severance: In the event of termination without cause (and execution of a release), the officer is entitled to six months of base salary or until the end of the contract term, whichever is sooner, plus accelerated option vesting.
- Change of Control: Similar severance and option acceleration apply if the officer terminates employment following a sale of the business due to an inability to reach an agreement with a successor entity.
- Termination for Cause/Resignation: Results in forfeiture of unvested options and payment only of accrued salary/bonuses.
- Restrictive Covenants: Includes non-compete and non-solicitation agreements during employment and for the duration of any severance payments.
Investor Verification Checklist
- Verify the total number of unvested stock options held by Gerald Kochanski to assess the potential cost of the new acceleration clause.
- Review the specific definitions of "cause" and "corporate targets" in the full agreement (Exhibit 10.60) to understand performance risks.
- Confirm the company's current cash position to ensure it can meet potential severance obligations (up to six months of salary) if triggered.
- Check for any subsequent filings regarding the actual vesting of options or changes to the compensation committee's targets.